Literature DB >> 8585551

Sequential therapy in the hospital management of lower respiratory infections.

F Vogel1.   

Abstract

Conventional treatment for patients hospitalized with lower respiratory infections, such as pneumonia or bronchitis, typically consists of parenteral antibiotic therapy for 7-10 days. The clinical evidence, however, shows that in most patients the objective and subjective indicators of infection are substantially improved within the first 2 days of treatment. Thus, many of these patients can be switched to oral antibiotics after 2-3 days of parenteral therapy, with no loss in efficacy of treatment and with substantial savings in terms of cost of care and length of hospital stay. beta-Lactam antibiotics are a frequent choice for the oral component following short-term intravenous therapy. The results of recent, large-scale comparative clinical trials support the usefulness of this treatment approach, known as sequential therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585551     DOI: 10.1016/s0002-9343(99)80305-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients.

Authors:  D N Fish; E Abraham
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents?

Authors:  Friedrich Vogel
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Intravenous and oral antibiotics in respiratory tract infection: an international observational study of hospital practice.

Authors:  J Cooke; M Kubin; T Morris; J Ribas; I Krämer; W Kämmerer; R Fornaini; A C Ballet; P P Sagnier
Journal:  Pharm World Sci       Date:  2002-12

4.  Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.

Authors:  D Genné; H H Siegrist; L Humair; B Janin-Jaquat; A de Torrenté
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.